Jefferies Group Analysts Increase Earnings Estimates for PRA Health Sciences, Inc. (PRAH)

PRA Health Sciences, Inc. (NASDAQ:PRAH) – Research analysts at Jefferies Group boosted their Q4 2017 earnings estimates for PRA Health Sciences in a research note issued to investors on Monday. Jefferies Group analyst D. Windley now forecasts that the medical research company will earn $0.91 per share for the quarter, up from their previous forecast of $0.89. Jefferies Group currently has a “Buy” rating and a $92.00 target price on the stock.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Monday, August 7th. The medical research company reported $0.62 EPS for the quarter, missing analysts’ consensus estimates of $0.72 by ($0.10). PRA Health Sciences had a return on equity of 21.17% and a net margin of 5.15%. The business had revenue of $457.90 million for the quarter, compared to the consensus estimate of $447.79 million. During the same period in the prior year, the business posted $0.63 earnings per share. PRA Health Sciences’s revenue was up .5% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: This article was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/2957561/jefferies-group-analysts-increase-earnings-estimates-for-pra-health-sciences-inc-prah.html.

Several other equities research analysts have also recently weighed in on the company. BidaskClub cut PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Citigroup Inc. reiterated a “buy” rating and set a $90.00 price target (up from $73.00) on shares of PRA Health Sciences in a research report on Wednesday, June 28th. Bank of America Corporation initiated coverage on PRA Health Sciences in a research report on Monday, June 26th. They set a “buy” rating and a $89.00 price target on the stock. Zacks Investment Research upgraded PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a research report on Tuesday, August 15th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating on shares of PRA Health Sciences in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $84.78.

PRA Health Sciences (NASDAQ PRAH) traded down 0.07% during trading on Wednesday, reaching $81.38. 55,404 shares of the company were exchanged. The stock has a market capitalization of $5.10 billion, a price-to-earnings ratio of 52.54 and a beta of 0.42. PRA Health Sciences has a one year low of $50.87 and a one year high of $82.00. The firm’s 50 day moving average price is $76.93 and its 200-day moving average price is $72.64.

A number of institutional investors and hedge funds have recently modified their holdings of the business. First Bank & Trust boosted its stake in PRA Health Sciences by 1.6% in the second quarter. First Bank & Trust now owns 3,211 shares of the medical research company’s stock worth $241,000 after buying an additional 52 shares in the last quarter. Renaissance Group LLC boosted its stake in PRA Health Sciences by 2.5% in the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock worth $393,000 after buying an additional 126 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its stake in PRA Health Sciences by 1.9% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after buying an additional 160 shares in the last quarter. Finally, Eqis Capital Management Inc. boosted its stake in PRA Health Sciences by 6.5% in the second quarter. Eqis Capital Management Inc. now owns 4,217 shares of the medical research company’s stock worth $316,000 after buying an additional 259 shares in the last quarter. 98.37% of the stock is owned by institutional investors and hedge funds.

In related news, VP Linda Baddour sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $74.85, for a total value of $7,485,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Colin Shannon sold 400,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $74.85, for a total transaction of $29,940,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,000,000 shares of company stock worth $748,500,000. 2.10% of the stock is owned by company insiders.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.